Clinical Trial Update: Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD [Phase 3]

View source ↗

Summary

Phase 3 safety follow-up study of remestemcel-L in pediatric patients with acute graft-versus-host disease that failed to respond to steroids; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Remestemcel-L (mesenchymal stromal cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-03-16